Pimecrolimus interferes the therapeutic efficacy of human mesenchymal stem cells in atopic dermatitis by regulating NFAT-COX2 signaling.

Nari ShinNamhee JungSeung-Eun LeeDasom KongNam Gyo KimMyung Geun KookHwanhee ParkSoon Won ChoiSeunghee LeeKyung Sun Kang

Published in: Stem cell research & therapy (2021)

Coadministration of pimecrolimus with hMSCs could interfere with the therapeutic efficacy of hMSCs in atopic dermatitis, and this is the first study that figured out the interaction of hMSCs with other drugs in cell therapy of atopic dermatitis. Therefore, this study might give rise to improvement of the clinical application of hMSCs therapy and facilitate the widespread application of hMSCs in clinical field.

Keyphrases

atopic dermatitis
cell therapy
mesenchymal stem cells
endothelial cells
stem cells
immune response
bone marrow
nuclear factor